Transglutaminase-catalyzed covalent

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY European Journal of Pharmaceutics and Biopharmaceutics Pub Date : 2024-08-26 DOI:10.1016/j.ejpb.2024.114462
Prisca Hamm , Denise Beckmann , Rafael Worschech , Alexandra Braun , Marcus Gutmann , Adelheid Korb-Pap , Tessa Lühmann , Thomas Pap , Lorenz Meinel
{"title":"Transglutaminase-catalyzed covalent","authors":"Prisca Hamm ,&nbsp;Denise Beckmann ,&nbsp;Rafael Worschech ,&nbsp;Alexandra Braun ,&nbsp;Marcus Gutmann ,&nbsp;Adelheid Korb-Pap ,&nbsp;Tessa Lühmann ,&nbsp;Thomas Pap ,&nbsp;Lorenz Meinel","doi":"10.1016/j.ejpb.2024.114462","DOIUrl":null,"url":null,"abstract":"<div><p>Nature realizes protein and peptide depots by catalyzing covalent bonds with the <strong>e</strong>xtra<strong>c</strong>ellular <strong>m</strong>atrix (ECM) of tissues. We are translating this natural blueprint for the sustained delivery of a myostatin-inhibiting peptide (Anti-Myo), resulting in an enzyme depot established from injectable solutions. For that, we fused Anti-Myo to the D-domain of insulin-like growth factor I, a <strong>t</strong>rans<strong>g</strong>lutaminase (TG) substrate. TG catalyzed the covalent binding of the D-domain to ECM proteins, such as laminin and fibronectin, on bioengineered ECM and in mice. ECM decorated with Anti-Myo suppressed myostatin activity and pathway activation and reduced the differentiation of preconditioned bone marrow-derived macrophages into osteoclasts in vitro.</p></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"203 ","pages":"Article 114462"},"PeriodicalIF":4.4000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0939641124002881/pdfft?md5=2d348b334f8e48d4c0bb55a457cbc3b5&pid=1-s2.0-S0939641124002881-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641124002881","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Nature realizes protein and peptide depots by catalyzing covalent bonds with the extracellular matrix (ECM) of tissues. We are translating this natural blueprint for the sustained delivery of a myostatin-inhibiting peptide (Anti-Myo), resulting in an enzyme depot established from injectable solutions. For that, we fused Anti-Myo to the D-domain of insulin-like growth factor I, a transglutaminase (TG) substrate. TG catalyzed the covalent binding of the D-domain to ECM proteins, such as laminin and fibronectin, on bioengineered ECM and in mice. ECM decorated with Anti-Myo suppressed myostatin activity and pathway activation and reduced the differentiation of preconditioned bone marrow-derived macrophages into osteoclasts in vitro.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
转谷氨酰胺酶催化的共价作用。
大自然通过催化与组织细胞外基质(ECM)的共价键来实现蛋白质和肽的储存。我们正在将这一自然蓝图转化为肌节蛋白抑制肽(Anti-Myo)的持续递送,从而通过注射溶液建立酶库。为此,我们将 Anti-Myo 与转谷氨酰胺酶(TG)底物胰岛素样生长因子 I 的 D 域融合。在生物工程 ECM 和小鼠体内,TG 可催化 D 域与层粘连蛋白和纤连蛋白等 ECM 蛋白的共价结合。用 Anti-Myo 装饰的 ECM 可抑制肌生成蛋白的活性和通路激活,并减少体外预处理的骨髓巨噬细胞向破骨细胞的分化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.80
自引率
4.10%
发文量
211
审稿时长
36 days
期刊介绍: The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.
期刊最新文献
A multifaceted approach to understanding protein-buffer interactions in biopharmaceuticals Continuous twin-screw melt granulation of drug-loaded electrospun fibers Homogeneity analysis of medicine tablets by laser induced breakdown spectroscopy combined with multivariate methods Antifungal peptide-loaded alginate microfiber wound dressing evaluated against Candida albicans in vitro and ex vivo Challenges in the development of long acting injectable multivesicular liposomes (DepoFoam® technology)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1